

Supplementary Table 1. Quality assessment of publications reporting pharmacokinetic parameters of cannabidiol in humans. Adapted from the NIH National Heart, Lung and Blood Institute, Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group.

Study	Q1	Q2	Q3	Q4	Q5	Q6	Overall
<i>Ohlsson, 1986[32]</i>	Good	Poor	Fair	Poor	Good	Good	Fair
<i>Consroe, 1991[35]</i>	Good	Poor	Poor	Fair	Good	Good	Fair
<i>Guy, 2004[20]</i>	Good	Good	Good	Poor	Good	Good	Good
<i>Guy, 2004[18]</i>	Good	Good	Fair	Good	Good	Good	Good
<i>Guy, 2004[19]</i>	Good	Good	Good	Fair	Good	Good	Good
<i>Nadulski, 2005[28]</i>	Good	Fair	Good	Good	Good	Good	Good
<i>Nadulski, 2005[29]</i>	Good	Poor	Good	Good	Good	Good	Good
<i>Karschner, 2011[21]</i>	Good	Good	Fair	Poor	Good	Good	Good
<i>Schwope, 2011[33]</i>	Good	Good	Fair	Poor	Fair	Good	Good
<i>Eichler, 2012[52]</i>	Good	Good	Fair	Poor	Good	Good	Good
<i>Lee, 2012[53]</i>	Good	Good	Fair	Poor	Fair	Good	Good
<i>Sellers, 2013[24]</i>	Good	Good	Good	Good	Good	Good	Good
<i>Stott, 2013[36]</i>	Good	Good	Fair	Good	Good	Good	Good
<i>Stott, 2013[25]</i>	Good	Good	Fair	Fair	Good	Good	Good
<i>Stott, 2013[23]</i>	Good	Good	Fair	Good	Good	Good	Good
<i>Newmeyer, 2014[54]</i>	Good	Good	Fair	Good	Fair	Good	Good
<i>Desrosiers, 2014[34]</i>	Good	Good	Fair	Good	Good	Good	Good
<i>Manini, 2015[26]</i>	Good	Good	Good	Fair	Good	Good	Good
<i>Haney, 2016[27]</i>	Good	Good	Good	Poor	Good	Good	Good
<i>Cherniakov, 2017[30]</i>	Good	Good	Fair	Poor	Good	Good	Good
<i>Swortwood, 2017[55]</i>	Good	Good	Fair	Good	Good	Good	Good
<i>Atsmon, 2017[31]</i>	Good	Good	Fair	Fair	Good	Good	Good
<i>Atsmon, 2017[22]</i>	Good	Good	Fair	Fair	Good	Good	Good
<i>Devinsky, 2018[17]</i>	Good	Fair	Good	Good	Fair	Good	Good

Q1: Was the study question or objective clearly stated?; **Q2:** Were eligibility/selection criteria for the study population pre-specified and clearly described?; **Q3:** Were the participants in the study representative of the general population?; **Q4:** Was the sample size sufficiently large to provide confidence in the findings?; **Q5:** Was the test/service/intervention (i.e. cannabidiol administration) clearly described and delivered consistently across the study population?; **Q6:** Were the outcome measures (i.e. pharmacokinetic parameters) pre-specified, clearly defined, valid, reliable, and assessed consistently across all study participants?

¹A sample size of ≤ 10 was considered poor, between 11 and 19 was considered fair, and ≥ 20 was considered good, based on Ogunbenro *et al.* (2006), J Biopharm Stat.